Global Anti-Epilepsy Drugs Market Forecast 2017-2027

LONDON, May 17, 2017 /PRNewswire/ --

First-Generation Drugs, Second-Generation Drugs, Third-Generation Drugs, Vimpat, Keppra, Briviact, Lamictal, Potiga/Trobalt, Lyrica, Neurontin

The global anti-epilepsy drugs market is expected to grow at a CAGR of 3.8% in the first half of the forecast period and CAGR of 5.0% in the second half of the forecast period. The market is estimated at $4.3bn in 2016 and $6.9bn in 2027.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 145-page report you will receive 100 charts - all unavailable elsewhere.

The 145-page report provides clear detailed insight into the global anti-epilepsy drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope 

• Global Anti-Epilepsy Drugs Market forecasts from 2017-2027

• Along with revenue prediction for the overall world market for anti-epilepsy drugs, our investigation shows forecasts to 2027 for the leading submarkets:
- First-generation Drugs
- Second-generation Drugs
- Third-generation Drugs
- Others

• This report also discusses the leading anti-epilepsy drugs:
- Vimpat
- Keppra
- Briviact
- Lamictal
- Potiga/Trobalt
- Lyrica
- Neurontin

• Our analyses show individual revenue forecasts to 2027 for these regional markets:
- US
- Japan
- EU5
- BRIC
- RoW

• This report provides historical and forecast of epilepsy prevalence in the US, Japan, France, Germany, Spain, Italy, and the UK

• This report covers pricing and reimbursement overview of the anti-epilepsy drugs market

• This report discusses selected pipeline molecules which are under development for the treatment of epilepsy

• Our study also identifies and discusses the leading companies in the anti-epilepsy drugs market

• Our study discusses drivers, challenges, and trends of the anti-epilepsy drugs market from 2016

Visiongain's study is intended for anyone requiring commercial analyses for the anti-epilepsy drugs market. You find data, trends and predictions.

Buy our report today Global Anti-Epilepsy Drugs Market Forecast 2017-2027: First-Generation Drugs, Second-Generation Drugs, Third-Generation Drugs, Vimpat, Keppra, Briviact, Lamictal, Potiga/Trobalt, Lyrica, Neurontin.

To see a report overview please email Sara Peerun on sara.peerun@visiongain.com

List of Companies and Organizations Mentioned in the Report 

Abide Therapeutics

Advicenne Pharma SA

Alexza Pharmaceuticals

American Epilepsy Society

Argentum Pharmaceuticals

Biscayne Neurotherapeutics

Canadian Agency for Drugs and Technologies in Health (CADTH)

Catalyst Pharmaceuticals

Centers for Disease Control (CDC)

Eisai

European Medicines Agency (EMA)

Food and Drug Administration (FDA)

GlaxoSmithKline (GSK)

Grifols S.A.

GW Pharmaceuticals

International League Against Epilepsy (ILAE)

Italian Medicines Agency (AIFA)

Janssen Pharmaceuticals

Japanese Ministry of Health, Labour and Welfare (MHLW)

Marinus Pharmaceuticals

National Institute of Neurological Disorders and Stroke

Novartis

Otsuka Pharmaceuticals

Pfizer

Pharmaceutical Benefits Advisory Committee (PBAC)

Proximagen

PTC Therapeutics

Roche

Sage Therapeutics

Sanofi

Scottish Medicines Consortium (SMC)

SK Biopharmaceuticals

Takeda

The National Institute for Health and Care Excellence (NICE)

UCB

Upsher-Smith Laboratories

World Health Organization (WHO)

Zogenix

To request a report overview of this report please email Sara Peerun at sara.peerun@visiongain.com or call Tel: +44-(0)-20-7336-6100

Or click on  https://www.visiongain.com/Report/1869/Global-Anti-Epilepsy-Drugs-Market-Forecast-2017-2027

To see a report overview please email Sara Peerun on sara.peerun@visiongain.com